TrialJournal of neuromuscular diseases2025

Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.

Ali A Habib et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.